MTOR and head and neck squamous cell carcinoma: In addition to monotherapies, combination treatments are scheduled with the PI3K/mTOR inhibitor gedatolisib and the cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, and HNSCC patients are currently being recruited for this Phase I trial (NCT03065062).